[HTML][HTML] Epidemiology and screening for renal cancer

SH Rossi, T Klatte, J Usher-Smith, GD Stewart - World journal of urology, 2018 - Springer
Purpose The widespread use of abdominal imaging has affected the epidemiology of renal
cell carcinoma (RCC). Despite this, over 25% of individuals with RCC have evidence of …

[PDF][PDF] Circulating DNA fragmentomics and cancer screening

AR Thierry - Cell Genomics, 2023 - cell.com
The high fragmentation of nuclear circulating DNA (cirDNA) relies on chromatin organization
and protection or packaging within mononucleosomes, the smallest and the most stabilized …

Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis

D Madhavan, M Wallwiener, K Bents… - Breast cancer research …, 2014 - Springer
Circulating or cell-free DNA (cfDNA) has been evaluated as a biomarker in many cancers
including breast cancer. In particular, integrity of cfDNA has been shown to be altered in …

[HTML][HTML] Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer

TB Hao, W Shi, XJ Shen, J Qi, XH Wu, Y Wu… - British journal of …, 2014 - nature.com
Background: To verify whether the concentrations and integrity index of circulating cell-free
DNA (ccf-DNA) in serum may be clinically useful for the diagnosis and progression …

Cell-free DNA: the role in pathophysiology and as a biomarker in kidney diseases

P Celec, B Vlková, L Lauková, J Bábíčková… - Expert reviews in …, 2018 - cambridge.org
Cell-free DNA (cfDNA) is present in various body fluids and originates mostly from blood
cells. In specific conditions, circulating cfDNA might be derived from tumours, donor organs …

Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers

MC Maia, M Salgia, SK Pal - Nature Reviews Urology, 2020 - nature.com
In the era of precision oncology, liquid biopsy techniques, especially the use of plasma
circulating tumour DNA (ctDNA) analysis, represent a paradigm shift in the use of genomic …

[HTML][HTML] Circulating cell-free DNA in renal cell carcinoma: the new era of precision medicine

E Francini, GN Fanelli, F Pederzoli, S Spisak… - Cancers, 2022 - mdpi.com
Simple Summary Early diagnosis of renal cell carcinoma (RCC) is challenging and typically
incidental. Currently, several therapeutic strategies are used for the treatment; however, no …

Cell-free DNA and RNA—measurement and applications in clinical diagnostics with focus on metabolic disorders

MH Drag, TO Kilpeläinen - Physiological genomics, 2021 - journals.physiology.org
Circulating cell-free DNA (cfDNA) and RNA (cfRNA) hold enormous potential as a new class
of biomarkers for the development of noninvasive liquid biopsies in many diseases and …

[HTML][HTML] Concentration and methylation of cell-free DNA from blood plasma as diagnostic markers of renal cancer

I Skrypkina, L Tsyba, K Onyshchenko, D Morderer… - Disease …, 2016 - hindawi.com
The critical point for successful treatment of cancer is diagnosis at early stages of tumor
development. Cancer cell-specific methylated DNA has been found in the blood of cancer …

[HTML][HTML] Increased level and fragmentation of plasma circulating cell-free DNA are diagnostic and prognostic markers for renal cell carcinoma

Y Yamamoto, M Uemura, K Nakano, Y Hayashi… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Background Reliable biomarkers for renal cell carcinoma (RCC) have yet to be found.
Circulating cell-free DNA (cfDNA) is an emerging resource for the diagnosis and prognosis …